First-line chemotherapy plus immunotherapy in biliary tract cancer

被引：3
|
作者：
Neuzillet, Cindy [1 ]
机构：
[1] Paris Saclay Univ, Versailles St Quentin Univ, Curie Inst, Dept Med Oncol, F-92210 St Cloud, France
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2022年 / 7卷 / 06期
关键词：
D O I：
10.1016/S2468-1253(22)00052-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：496 / 497
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
    Slater, Susanna
    Cunningham, David
    LANCET, 2023, 401 (10391): : 1826 - 1827
  • [2] EFFICACY AND SAFETY OF GEMCITABINE PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED BILIARY TRACT CANCER
    Oka, Y.
    Todaka, A.
    Fukutomi, A.
    Tsushima, T.
    Yokota, T.
    Machida, N.
    Yamazaki, K.
    Onozawa, Y.
    Boku, N.
    Yasui, H.
    ANNALS OF ONCOLOGY, 2013, 24 : 44 - 44
  • [3] FIRST-LINE CHEMOTHERAPY IN ADVANCED BILIARY TRACT CANCER: AN AUSTRALIAN EXPERIENCE
    Brungs, D.
    Aghmesheh, M.
    Sjoquist, K.
    Goldstein, D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 51 - 51
  • [4] Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
    Ye, Zhuo-miao
    Xu, Zhe
    Li, Huan
    Li, Qian
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [5] Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer
    Park, Kwonoh
    Kim, Kyu-pyo
    Park, Seongjoon
    Chang, Heung-Moon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (01) : 13 - 20
  • [6] Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study
    Woo, Sang Myung
    Lee, Woo Jin
    Han, Sung-Sik
    Park, Sang-Jae
    Kim, Tae Hyun
    Koh, Young Hwan
    Kim, Hyun Bum
    Hong, Eun Kyung
    Park, Joong-Won
    Kim, Chang-Min
    CHEMOTHERAPY, 2012, 58 (03) : 225 - 232
  • [7] Predictive factors of outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
    Suzuki, Y.
    Kan, M.
    Kimura, G.
    Umemoto, K.
    Watanabe, K.
    Sasaki, M.
    Takahashi, H.
    Hashimoto, Y.
    Imaoka, H.
    Ohno, I.
    Mitsunaga, S.
    Ikeda, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Gemcitabine plus Cisplatin versus Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Cohort Study
    Woo, Sang Myung
    Lee, Woo Jin
    Kim, Ji Hun
    Kim, Dong Hwan
    Han, Sung-Sik
    Park, Sang-Jae
    Kim, Tae Hyun
    Lee, Ju Hee
    Koh, Young Hwan
    Hong, Eun Kyung
    CHEMOTHERAPY, 2013, 59 (03) : 232 - 238
  • [9] FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)
    Ulusakarya, A.
    Karray, W.
    Abdou, J.
    Karaboue, A.
    Haydar, M.
    Krimi, S.
    Gumus, Y.
    Almohamad, W.
    Goldschmidt, E.
    Biondani, P.
    Morere, J. F.
    ANNALS OF ONCOLOGY, 2018, 29 : 260 - 260
  • [10] A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy
    Filippi, Roberto
    Montagnani, Francesco
    Lombardi, Pasquale
    Fornaro, Lorenzo
    Aprile, Giuseppe
    Casadei-Gardini, Andrea
    Faloppi, Luca
    Palloni, Andrea
    Satolli, Maria Antonietta
    Scartozzi, Mario
    Citarella, Fabrizio
    Lutrino, Stefania Eufemia
    Vivaldi, Caterina
    Silvestris, Nicola
    Rovesti, Giulia
    Rimini, Margherita
    Aglietta, Massimo
    Brandi, Giovanni
    Leone, Francesco
    ACTA ONCOLOGICA, 2021, 60 (10) : 1317 - 1324
12345